In Nature Portfolio, Francisco Sánchez-Rivera discusses his collaboration with Agilent Technologies to develop a tool reliable enough to support his work in precision genome editing. Sánchez-Rivera studies the impact of individual sequence mutations on cancer development, with an eye toward understanding how these mutations alter tumor response to therapy.